Cargando…

Combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules

BACKGROUND: Improving the water solubility of hydrophobic drugs, increasing their accumulation in tumor tissue and allowing their simultaneous action by different pathways are essential issues for a successful chemotherapeutic activity in cancer treatment. Considering potential clinical application...

Descripción completa

Detalles Bibliográficos
Autores principales: Villar-Alvarez, E., Cambón, A., Pardo, A., Arellano, L., Marcos, A. V., Pelaz, B., del Pino, P., Bouzas Mosquera, A., Mosquera, V. X., Almodlej, A., Prieto, G., Barbosa, S., Taboada, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794818/
https://www.ncbi.nlm.nih.gov/pubmed/31615570
http://dx.doi.org/10.1186/s12951-019-0538-3
_version_ 1783459369743024128
author Villar-Alvarez, E.
Cambón, A.
Pardo, A.
Arellano, L.
Marcos, A. V.
Pelaz, B.
del Pino, P.
Bouzas Mosquera, A.
Mosquera, V. X.
Almodlej, A.
Prieto, G.
Barbosa, S.
Taboada, P.
author_facet Villar-Alvarez, E.
Cambón, A.
Pardo, A.
Arellano, L.
Marcos, A. V.
Pelaz, B.
del Pino, P.
Bouzas Mosquera, A.
Mosquera, V. X.
Almodlej, A.
Prieto, G.
Barbosa, S.
Taboada, P.
author_sort Villar-Alvarez, E.
collection PubMed
description BACKGROUND: Improving the water solubility of hydrophobic drugs, increasing their accumulation in tumor tissue and allowing their simultaneous action by different pathways are essential issues for a successful chemotherapeutic activity in cancer treatment. Considering potential clinical application in the future, it will be promising to achieve such purposes by developing new biocompatible hybrid nanocarriers with multimodal therapeutic activity. RESULTS: We designed and characterised a hybrid nanocarrier based on human serum albumin/chitosan nanoparticles (HSA/chitosan NPs) able to encapsulate free docetaxel (DTX) and doxorubicin-modified gold nanorods (DOXO-GNRs) to simultaneously exploit the complementary chemotherapeutic activities of both antineoplasic compounds together with the plasmonic optical properties of the embedded GNRs for plasmonic-based photothermal therapy (PPTT). DOXO was assembled onto GNR surfaces following a layer-by-layer (LbL) coating strategy, which allowed to partially control its release quasi-independently release regarding DTX under the use of near infrared (NIR)-light laser stimulation of GNRs. In vitro cytotoxicity experiments using triple negative breast MDA-MB-231 cancer cells showed that the developed dual drug encapsulation approach produces a strong synergistic toxic effect to tumoral cells compared to the administration of the combined free drugs; additionally, PPTT enhances the cytostatic efficacy allowing cell toxicities close to 90% after a single low irradiation dose and keeping apoptosis as the main cell death mechanism. CONCLUSIONS: This work demonstrates that by means of a rational design, a single hybrid nanoconstruct can simultaneously supply complementary therapeutic strategies to treat tumors and, in particular, metastatic breast cancers with good results making use of its stimuli-responsiveness as well as its inherent physico-chemical properties. [Image: see text]
format Online
Article
Text
id pubmed-6794818
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67948182019-10-21 Combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules Villar-Alvarez, E. Cambón, A. Pardo, A. Arellano, L. Marcos, A. V. Pelaz, B. del Pino, P. Bouzas Mosquera, A. Mosquera, V. X. Almodlej, A. Prieto, G. Barbosa, S. Taboada, P. J Nanobiotechnology Research BACKGROUND: Improving the water solubility of hydrophobic drugs, increasing their accumulation in tumor tissue and allowing their simultaneous action by different pathways are essential issues for a successful chemotherapeutic activity in cancer treatment. Considering potential clinical application in the future, it will be promising to achieve such purposes by developing new biocompatible hybrid nanocarriers with multimodal therapeutic activity. RESULTS: We designed and characterised a hybrid nanocarrier based on human serum albumin/chitosan nanoparticles (HSA/chitosan NPs) able to encapsulate free docetaxel (DTX) and doxorubicin-modified gold nanorods (DOXO-GNRs) to simultaneously exploit the complementary chemotherapeutic activities of both antineoplasic compounds together with the plasmonic optical properties of the embedded GNRs for plasmonic-based photothermal therapy (PPTT). DOXO was assembled onto GNR surfaces following a layer-by-layer (LbL) coating strategy, which allowed to partially control its release quasi-independently release regarding DTX under the use of near infrared (NIR)-light laser stimulation of GNRs. In vitro cytotoxicity experiments using triple negative breast MDA-MB-231 cancer cells showed that the developed dual drug encapsulation approach produces a strong synergistic toxic effect to tumoral cells compared to the administration of the combined free drugs; additionally, PPTT enhances the cytostatic efficacy allowing cell toxicities close to 90% after a single low irradiation dose and keeping apoptosis as the main cell death mechanism. CONCLUSIONS: This work demonstrates that by means of a rational design, a single hybrid nanoconstruct can simultaneously supply complementary therapeutic strategies to treat tumors and, in particular, metastatic breast cancers with good results making use of its stimuli-responsiveness as well as its inherent physico-chemical properties. [Image: see text] BioMed Central 2019-10-15 /pmc/articles/PMC6794818/ /pubmed/31615570 http://dx.doi.org/10.1186/s12951-019-0538-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Villar-Alvarez, E.
Cambón, A.
Pardo, A.
Arellano, L.
Marcos, A. V.
Pelaz, B.
del Pino, P.
Bouzas Mosquera, A.
Mosquera, V. X.
Almodlej, A.
Prieto, G.
Barbosa, S.
Taboada, P.
Combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules
title Combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules
title_full Combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules
title_fullStr Combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules
title_full_unstemmed Combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules
title_short Combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules
title_sort combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794818/
https://www.ncbi.nlm.nih.gov/pubmed/31615570
http://dx.doi.org/10.1186/s12951-019-0538-3
work_keys_str_mv AT villaralvareze combinationoflightdrivencodeliveryofchemodrugsandplasmonicinducedheatforcancertherapeuticsusinghybridproteinnanocapsules
AT cambona combinationoflightdrivencodeliveryofchemodrugsandplasmonicinducedheatforcancertherapeuticsusinghybridproteinnanocapsules
AT pardoa combinationoflightdrivencodeliveryofchemodrugsandplasmonicinducedheatforcancertherapeuticsusinghybridproteinnanocapsules
AT arellanol combinationoflightdrivencodeliveryofchemodrugsandplasmonicinducedheatforcancertherapeuticsusinghybridproteinnanocapsules
AT marcosav combinationoflightdrivencodeliveryofchemodrugsandplasmonicinducedheatforcancertherapeuticsusinghybridproteinnanocapsules
AT pelazb combinationoflightdrivencodeliveryofchemodrugsandplasmonicinducedheatforcancertherapeuticsusinghybridproteinnanocapsules
AT delpinop combinationoflightdrivencodeliveryofchemodrugsandplasmonicinducedheatforcancertherapeuticsusinghybridproteinnanocapsules
AT bouzasmosqueraa combinationoflightdrivencodeliveryofchemodrugsandplasmonicinducedheatforcancertherapeuticsusinghybridproteinnanocapsules
AT mosqueravx combinationoflightdrivencodeliveryofchemodrugsandplasmonicinducedheatforcancertherapeuticsusinghybridproteinnanocapsules
AT almodleja combinationoflightdrivencodeliveryofchemodrugsandplasmonicinducedheatforcancertherapeuticsusinghybridproteinnanocapsules
AT prietog combinationoflightdrivencodeliveryofchemodrugsandplasmonicinducedheatforcancertherapeuticsusinghybridproteinnanocapsules
AT barbosas combinationoflightdrivencodeliveryofchemodrugsandplasmonicinducedheatforcancertherapeuticsusinghybridproteinnanocapsules
AT taboadap combinationoflightdrivencodeliveryofchemodrugsandplasmonicinducedheatforcancertherapeuticsusinghybridproteinnanocapsules